Tenofovi-Emtricitabine (TDF/FTC) tablet

DRUG3 trials

Sponsors

Bristol-Myers Squibb, Desmond Tutu HIV Foundation, Oswaldo Cruz Foundation

Conditions

Contact With or Exposure to Human Immunodeficiency VirusHIVHIV Infections

Phase 3

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

CompletedNCT00272779

Bristol-Myers SquibbHIV Infections

Start: 2005-11-30End: 2008-10-31Updated: 2011-05-09

Unknown Phase

ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.

Not yet recruitingNCT07390409

Desmond Tutu HIV FoundationHIV

Start: 2026-01-29End: 2028-05-01Target: 3700Updated: 2026-02-05

ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention

RecruitingNCT07497594

Oswaldo Cruz FoundationContact With or Exposure to Human Immunodeficiency Virus

Start: 2026-02-03End: 2029-09-01Target: 1500Updated: 2026-03-27

Related Papers

Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.

2011-11-2517 citations

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.

2010-12-0935 citations

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

2008-08-01267 citations